Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYP-6589 in Advanced Solid Tumors and NSCLC
NCT06712680Phase 2Recruiting
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HY-0006 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicity at 24 days, Treatment-Emergent Adverse Events up to 2 years and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
HY-0006
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06712680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712680.